A common role for psychotropic medications: Memory impairment

Medical Hypotheses

Volumn 60, Issue 1, 2003, Pages 133-142

  Parra, Andrés ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUTYROPHENONE; CLOZAPINE; DESIPRAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; IMIPRAMINE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; GENETIC ASSOCIATION; HUMAN; HYPOTHESIS; LEARNING; MEMORY; MEMORY DISORDER; MENTAL DISEASE; MENTAL TEST; NERVOUS SYSTEM; NEUROBIOLOGY; PRIORITY JOURNAL;

EID: 0037221320     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00350-X     Document Type: Article

References (85)

1. Gumnick J. F, Nemeroff C. B Problems with currently available antidepressants. J Clin Psychiatry 2000; 61(S10): 5-15.
2. Stahl S. M., Nierenberg A. A., Gorman J. M. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001; 62(suppl. 4): 17-23.
3. Tyrer P. J. Drugs in Psychiatric Practice. London: Butterworths, 1982.
4. Stassen H. H., Angst J., Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry 1996; 29: 87-96.
5. Lindström E., Bingefors K. Patient compliance with drug therapy in schizophrenia Economic and clinical issues. Pharmacoeconomics 2000; 18: 105-124.
6. Simon G. E., VonKorff M., Heiligenstein J. H., Revicki D. A., Grothaus L., Katon W., Wagner E. H. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275: 1897-1902.
7. Conley R. R., Kelly D. L. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50: 898-911.
8. + ratio might predict clinical responses. J Clin Pharm Ther 1999; 24: 141-143.
9. Hall I. P. Isoenzyme selective phosphodiesterase inhibitors: Potential clinical uses. Br J Clin Pharmacol 1993; 35: 1-7.
10. Meltzer H. Y. An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55(suppl. B): 47-52.
11. Horrobin D. F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
12. Peer M., HorrobinD. F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18.
13. Jope R. S. Anti-bipolar therapy: Mechanism of action of lithium. Mol Psychiatry 1999; 4: 117-128.
14. Van Praag H. M. Past expectations, present disappointments, future hopes or psychopathology as the rate-limiting step of progress in psychopharmacology. Hum Psychopharmacol Clin Exp 2001; 16: 3-7.
15. MacLean P. Introduction: Perspectives on cingulated cortex in the limbic system. In: B. A. Vogt, M. Gabriel (eds). Neurobiology of Cingulated Cortex and Limbic Thalamus: A Comprehensive Handbook. Boston: Birkhäuser, 1993: 1-15.
16. Fendt M., Fanselow M. S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 1999; 23: 743-760
17. Manji H. K., Drevets W. C., Charney D. S. The cellular neurobiology of depression. Nat Med 2001; 7: 541-547.
18. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 2001; 62: 77-91.
19. Lieberman J. A., Koreen A. R. Neurochemistry and neuroendocrinology of schizophrenia: A selective review. Schizophr Bull 1993; 19: 371-429.
20. Thompson R. F., Kim J. J. Memory systems in the brain and localization of a memory. Proc Natl Acad Sci USA 1996; 93: 13438-13444.
21. Kim J. J., Baxter M. G. Multiple brain-memory systems: The whole does not equal the sum of its parts. Trends Neurosci 2001; 24: 324-330.
22. Gaffan D. What is a memory system? Horel's critique revisited. Behav Brain Res 2001; 127: 5-11.
23. Steinmetz J. E. Brain substrates of classical eyeblink conditioning: A highly localized but also distributed system. Behav Brain Res 2000; 110: 13-24.
24. Gabriel M. Discriminative avoidance learning a model system. In: B. A. Vogt, M. Gabriel (eds). Neurobiology of Cingulated Cortex and Limbic Thalamus: A Comprehensive Handbook. Boston: Birkhäuser, 1993: 478-523.
25. Duman R. S., Heninger G. R., Nestler E. J. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
26. Duman R. S., Malberg J., Thome J. Neural plasticity to stress and antidepressant treatment. Biol Psychiatry 1999; 46: 1181-1191.
27. Nibuya M., Nestler E. J., Duman R. S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2365-2372.
28. Thome J., Sakai N., Shin K., Steffen C., Zhang Y. J., Impey S., Storm D., Duman R. S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci 2000; 20: 4030-4036.
29. Chen A. C., Shirayama Y., Shin K. H., Neve R. L., Duman R. S. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001; 49: 753-762.
30. Abel T., Lattal K. M. Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 2001; 11: 180-187.
31. + channel cascade. Trends Neurosci 1998; 21: 529-537.
32. Kandel E. R. The molecular biology of memory storage: A dialogue between genes and synapses. Science 2001; 294: 1030-1038.
33. Malberg J. E., Eisch A. J., Nestler E. J., Duman R. S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-9110.
34. Snyder J. S., Kee N., Wojtowicz J. M. Effects of adult neurogenesis on synaptic plasticity in the rat dentate gyrus. J Neurophysiol 2001; 85: 2423-2431.
35. Shors T. J., Miesegaes G., Beylin A., Zhao M., Rydel T., Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 2001; 410: 372-376.
36. Rescorla R. A. Experimental extinction. In: R. R. Rescorla Mowrer, S. B. Klein (eds). Handbook of Contemporary Learning Theories. Mahwah: LEA, 2001: 119-154.
37. Vianna M. R., Szapiro G., McGaugh J. L., Medina J. H., Izquierdo I. Retrieval of memory for fear-motivated training initiates extinction requiring protein synthesis in the rat hippocampus. Proc Natl Acad Sci USA 2001; 98: 12251-12254.
38. Amado-Boccara I., Gougoulis N., Poirier Littre M. F., Galinowski A., Loo H. Effects of antidepressants on cognitive functions: A review. Neurosci Biobehav Rev 1995; 19: 479-493.
39. Parra A., Martos A. J., Monleón S., Arenas M. C., Vinader-Caerols C. Effects of acute and chronic maprotiline administration on inhibitory avoidance in male mice. Behav Brain Res 2000; 109: 1-7.
40. McElroy J. F., Du Pont A. F., Feldman R. S. The effects of fenfluramine and fluoxetine on the acquisition of the conditioned avoidance response in rats. Psychopharmacology 1982; 77: 356-359.
41. Nelson C. J., Jordan W. P., Bohan R. T. Daily fluoxetine administration impairs avoidance learning in the rat without altering sensory thresholds. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 1043-1057.
42. Deutsch J. A. The cholinergic synapse and the site of memory. Science 1971; 174: 788-794.
43. Francis P. T., Palmer A. M., Snape M., Wilcock G. K. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 1999; 65: 137-147.
44. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: From indiscriminate to valid testing. Part I. Psychopharmacology 1992; 107: 144-159.
45. Sarter M., Hagan J., Dudchenko P. Behavioral screening for cognition enhancers: From indiscriminate to valid testing. Part II. Psychopharmacology 1992; 107: 461-473.
46. Geoffroy M., Scheel-Kruger J., Christensen A. V. Effect of imipramine in the 'leamed helplessness' model of depression in rats is not mimicked by combinations of specific reuptake inhibitors and scopolamine. Psychopharmacology 1990; 101: 371-375.
47. Seligman M. E. P. Helplessness. San Francisco: Freeman, 1975.
48. Martos A. J., Vinader-Caerols C., Monleón S., Arenas M C., Parra A. Efectos de la fisostigrnina y de la nicotina sobre la inmovilidad aprendida en la prueba de natación forzada. Psicothema 1999; 11: 631-639.
49. Parra A., Vinader-Caerols C., Monleón S., Simón V. M. Learned immobility is also involved in the forced swimming test in mice. Psicothema 1999; 11: 239-246.
50. Willner P. The validity of animal models of depression. Psychopharmacology 1984; 83: 1-16.
51. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999; 375: 31-40.
52. De Pablo J. M., Parra A., Segovia S., Guillamón A. Learned immobility explains the behavior of rats in the forced swimming test. Physiol Behav 1989; 46: 229-237.
53. Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50: 729-742.
54. Fibiger H. C., Zis A. P., Phillips A. G. Haloperidol-induced disruption of conditioned avoidance responding: Attenuation by prior training or by anticholinergic drugs. Eur J Pharmacol 1975; 30: 309-314.
55. Monleón S., Vinader-Caerols C., Parra A. Sex differences in escape-avoidance response in mice after acute administration of raclopride, clozapine and SCH 23390. Pharmacol Biochem Behav 1998; 60: 489-497.
56. Kuribara H., Tadokoro S. Effects of psychoactive drugs on conditioned avoidance response in mongolian gerbils (Meriones unguiculatus): Comparison with Wistar rats and dd mice. Pharmacol Biochem Behav 1985; 23: 1013-1018.
57. Niemegeers C. J. E., Verbrugen F. J., Jansen P. A. J. The influence of various neuroleptic drugs on shock avoidance responding in rats. I. Nondiscriminated Sidman avoidance procedure. Psychopharmacologia 1969; 16: 161-174.
58. Niemegeers C. J. E., Verbrugen F. J., Jansen P. A. J. The influence of various neuroleptic drugs on shock avoidance responding in rats. II. Nondiscriminated Sidman avoidance procedure with alternate reinforcement and extinction periods and analysis of the interresponse times (IRT's). Psychopharmacologia 1969; 16: 175-182.
59. Carey R. J., Kenney S. Operant conditioning and haloperidol-induced hypokinetic effects. Neuropsychobiology 1987; 18: 199-204.
60. Castellano C., Battaglia M., Sansone M. Oxiracetam prevents haloperidol-induced passive avoidance impairment in mice. Pharmacol Biochem Behav 1992; 42: 797-801.
61. Ploeger G. E., Spruijt B. M., Cools A. R. Effects of haloperidol on the acquisition of a spatial learning task. Physiol Behav 1992; 52: 979-983.
62. Sears L. L., Steinmetz J. E. Effects of haloperidol on sensory processing in the hippocampus during classical eyeblink conditioning. Psychopharmacology 1997; 130: 254-260.
63. Ljungberg T. Blockade by neuroleptics of water intake and operant responding for water in the rat: Anhedonia, motor deficit, or both? Pharmacol Biochem Behav 1987; 27: 341-350.
64. Horvitz J. C., Ettenberg A. Haloperidol blocks the response-reinstating effects of food reward: A methodology for separating neuroleptic effects on reinforcement and motor processes. Pharmacol Biochem Behav 1989; 31: 861-865.
65. Nakajima S., McKenzie G. M. Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390. Pharmacol Biochem Behav 1986; 24: 919-923.
66. Spyraki C., Fibiger H. C., Phillips A. G. Attenuation by haloperidol of place preference conditioning using food reinforcement. Psychopharmacology 1982; 77: 379-382.
67. Dalton J. C. H., Vickers G. J., Roberts D. C. S. Increased self-administration of cocaine following haloperidol: Sex-dependent effects of the antiestrogen tamoxifen. Pharmacol Biochem Behav 1986; 25: 497-501.
68. Ruob C., Weiner I., Feldon J. Haloperidol-induced potentiation of latent inhibition: Interaction with parameters of conditioning. Behav Pharmacol 1998; 9: 245-253.
69. Lubow R. E. Latent inhibition as a measure of learned inattention: Some problems and solutions. Behav Brain Res 1997; 88: 75-83.
70. Moser P. C., Hitchcock J. M., Lister S., Moran P. M. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Res Rev 2000; 33: 275-307.
71. Arenas M. C., Parra A., Simón V. M. Gender differences in the effects of haloperidol on avoidance conditioning in mice. Pharmacol Biochem Behav 1995; 51: 601-609.
72. Fowler S. C., Ford K. E., Gramling S. E., Nail G. L. Acute and subchronic effects of neuroleptics on quantitative measures of discriminative motor control in rats. Psychopharmacology 1984; 84: 368-373.
73. Parra A., Arenas M. C., Monleón S., Vinader-Caerols C., Simón V. M. Sex differences in the effects of neuroleptics on escape-avoidance behaviour in mice: A review. Pharmacol Biochem Behav 1999; 64: 813-820.
74. Amt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 1982; 51: 321-329.
75. Wadenberg M. L., Hicks P. B. The conditioned avoidance response test re-evaluated: Is it a sensitive test for the detection of potentially atypical antipsychotics. Neurosci Biobehav Rev 1999; 23: 851-862.
76. Vinader-Caerols C., Aguilar M. A, Pérez-Iranzo N., Miñarro J., Parra A., Simón V. M. Apparent vs. real effects of scopolamine on the learning of an active avoidance task. Neurobiol Learn Mem 1996; 66: 246-251.
77. Geyer M. A., Krebs-Thomson K., Braff D. L., Swerdlow N. R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: A decade in review. Psychopharmacology 2001; 156: 117-154.
78. Jones C. K., Shannon H. E. Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 2000; 294: 1017-1023.
79. Depoortere R., Perrault G., Sanger D. J. Prepulse inhibition of the startle reflex in rats: Effects of compounds acting at various sites on the NMDA receptor complex. Behav Pharmacol 1999; 10: 51-62.
80. Zhang W., Pouzet B., Jongen-Relo A. L., Weiner I., Feldon J. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: A possible model for the screening of atypical antipsychotics. Neuro Report 1999; 10: 2533-2538.
81. Kuhar M. J., Joyce A. R. Slow onset of CNS drugs: Can changes in protein concentration account for the delay. Trends Pharmacol Sci 2001; 22: 450-456.
82. Seligman M. E. P. On the generality of the laws of learning. Psychol Rev 1970; 77: 406-418.
83. Sandler M. E. P. Neurotrophins: Possible role in affective disorders. Hum Psychopharmacol Clin Exp 2001; 16: 61-64.
84. Tsukahara T., Iihara K., Hashimoto N., Nishijima T., Tardguchi T. Increases in levels of brain-derived neurotrophic factor mRNA and its promoters after transient forebrain ischemia in the rat brain. Neurochem Int 1998; 33: 201-207.
85. Weng G., Bhalla U. S., Iyengar R. Complexity in biological signaling systems. Science 1999; 284: 92-96.